All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
80 results for "Cancer" and "Eye/Orbital Cancers"
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
JNJ-64407564 [anti-GPRC5DxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, GPRC5D, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64407564 [anti-GPRC5DxCD3] brings these killer T-cells to the myeloma cell resulting in myeloma cell death.
JNJ-64007957 [anti-BCMAxCD3] is called a bispecific antibody because it has two arms that target a protein on the myeloma cells, BCMA, and a protein on T-cells, CD3. T-cells are a type of cell that can kill cancer cells. JNJ-64007957 [anti-BCMAxCD3] brings ...
Protocol No
JANSSEN-64407564MMY1002
A Multisite Phase IB Study of Pevonedistat, Azacitidine (or Decitabine) and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML.
Protocol No
IIT-ATALLAH-PAVE-AML
A multi-center single arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Dual CD20 and CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Sub Category
A Multicenter, Open-Label, Dose-Escalation Phase 1b Study Of AEVI-007 In Subjects With Relapsed Or Refractory Multiple Myeloma
AEVI-007,in the treatment of relapsed or refractory multiple myeloma.
Protocol No
AEVI-007-MM-101
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Molecular Evidence of Disease
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Protocol No
SWOG-S1712-CML
Sub Category
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
A Phase 1 Study of ADI-001 in B Cell Malignancies
Protocol No
ADICET-ADI-001-BCELL
Sub Category
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti0CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Sub Category
Descartes-11 Consolidation Treatment in Patients with High Risk Multiple Myeloma who have Residual Disease after Induction Therapy
Descartes-11 Consolidation Tx in Pts with HR-MM who have Residual Disease after Induction Therapy
Protocol No
CARTESIAN-DC11B-HR-MM
Sub Category
A Phase III, Randomized Study Of Nivolumab (OPDIVO) Plus AVD Or Brentuximab Vedotin (ADCETRIS) Plus AVD In Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Nivo plus AVD or BV plus AVD in newly diagnosed advanced HL
Protocol No
SWOG-S1826-HL
Sub Category
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy & Safety of Belantamab Mafodotin in Combination with Pomalidomide & Dex (B-Pd) versus Pomalidomide plus Bortezomib & Dex (PVd) in Participants with Relapsed/Refractory Multiple Myeloma
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Protocol No
GSK-207499-DREAMM-08
Sub Category
PrE0905-AML: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Protocol No
PRECOG-PRE0905-AML
Sub Category
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Protocol No
SUTRO-STRO-002-GM1
Sub Category
Daratumumab, Pomalidomide And Dexamethasone (Dpd) In Relapsed/ Refractory Light Chain Amyloidosis Patients Previously Exposed To Daratumumab
DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Protocol No
WEILLCORNELL-AMY2006-DPD
Sub Category
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia
Ropeginterferon Alfa-2b (P1101) v. Anagrelide in ET Patients w/Hydroxyurea Resistance or Intolerance
Protocol No
PHARMAESSENTIA-P1101-ET
Sub Category
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Triple Combination of Pevonedistat & Venetoclax Plus Azacitidine in Adults with AML Who Are Unfit for Intensive Chemotherapy
Protocol No
TAKEDA-TAK-P2002-AML
Sub Category
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
To compare the 3-year recurrence-free survival of women with high intermediate risk (HIR) stage I/II mismatch repair deficient (dMMR) endometrioid endometrial cancer treated with radiation and MK-3475 (pembrolizumab) versus radiation alone
Protocol No
NRG-GY020
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIb AL Amyloid
Protocol No
CAELUM-CAEL101-301
Sub Category
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
A Study to Evaluate the Effectiveness & Safety of CAEL-101 in Patients w/ Mayo Stage IIIa AL Amyloid
Protocol No
CAELUM-CAEL101-302
Sub Category
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Protocol No
TENEOBIO-TENEOTWO-TNB486-001
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Sub Category